PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population
- PMID: 20571907
- DOI: 10.1007/s11033-010-0236-6
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population
Abstract
The objective of the work was to study PIK3CA mutations in wild type KRAS and BRAF colorectal cancer. Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yagüe Hospital in Burgos. KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in all patients. PIK3CA mutations were present in 8.22% of wild type KRAS and BRAF colorectal cancers. The most frequent mutation is E545K/D in exon 9 which represents 83.3% of all mutations. By contrast, we did not found any tumour harbouring H1047R mutation in exon 20. Among the patients who undergo a curative resection of colorectal cancer, PIK3CA mutation is present in an important percentage of KRAS and BRAF wild type tumours. PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies.
Similar articles
-
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26. Int J Clin Oncol. 2013. PMID: 22638623
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739
-
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z. BMC Cancer. 2015. PMID: 25886136 Free PMC article.
-
[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].Nihon Rinsho. 2011 Apr;69 Suppl 3:477-81. Nihon Rinsho. 2011. PMID: 22214007 Review. Japanese. No abstract available.
-
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Cesk Patol. 2011 Oct;47(4):154-8. Cesk Patol. 2011. PMID: 22145213 Review. Czech.
Cited by
-
PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.PLoS One. 2013 Jun 13;8(6):e65479. doi: 10.1371/journal.pone.0065479. Print 2013. PLoS One. 2013. PMID: 23785428 Free PMC article.
-
Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.Cells. 2020 Apr 30;9(5):1116. doi: 10.3390/cells9051116. Cells. 2020. PMID: 32365913 Free PMC article.
-
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer.Oncol Lett. 2015 Sep;10(3):1423-1429. doi: 10.3892/ol.2015.3398. Epub 2015 Jun 19. Oncol Lett. 2015. PMID: 26622684 Free PMC article.
-
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.J Cancer. 2017 Aug 22;8(14):2713-2719. doi: 10.7150/jca.19458. eCollection 2017. J Cancer. 2017. PMID: 28928860 Free PMC article.
-
The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer.Pathol Oncol Res. 2016 Oct;22(4):707-14. doi: 10.1007/s12253-016-0056-7. Epub 2016 Mar 31. Pathol Oncol Res. 2016. PMID: 27033063
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous